Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FEOE | 56.75 | 1.65 | +2.99% |
| FIRST EAGLE OVERSEAS EQUITY ETF | |||
| DMAY | 48.18 | 0.47 | +0.99% |
| FT Vest U.S. Equity Deep Buffer ETF - May (DMAY) | |||
| ATTR | 96.50 | 0.26 | +0.27% |
| Arin Tactical Tail Risk ETF | |||
| APRZ | 40.47 | -0.19 | -0.46% |
| TrueShares Structured Outcome (April) ETF (APRZ) | |||
| CATG | 5.27 | -0.59 | -10.07% |
| Leverage Shares 2X Long CAT Daily ETF (CATG) | |||
A.I.dvisor indicates that over the last year, CBT has been loosely correlated with ASIX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CBT jumps, then ASIX could also see price increases.
a supplier of organic chemicals
Industry ChemicalsSpecialty
The RSI Oscillator for CBT moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 19 of the 22 cases the stock moved higher. This puts the odds of a move higher at 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 60 cases where CBT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CBT as a result. In 60 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for CBT just turned positive on October 22, 2026. Looking at past instances where CBT's MACD turned positive, the stock continued to rise in 31 of 49 cases over the following month. The odds of a continued upward trend are 63%.
Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBT advanced for three days, in 205 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
CBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for CBT moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for CBT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.416) is normal, around the industry mean (2.450). P/E Ratio (20.919) is within average values for comparable stocks, (-17.964). Projected Growth (PEG Ratio) (0.320) is also within normal values, averaging (1.548). Dividend Yield (0.025) settles around the average of (0.040) among similar stocks. P/S Ratio (1.138) is also within normal values, averaging (48.960).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. CBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock slightly better than average.